EBS FY 2016 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

FY 2016 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$489M-0.1% YoY

Gross Profit

$245M50.1% margin

Operating Income

$106M21.6% margin

Net Income

$52M10.6% margin

EPS (Diluted)

$1.13

Cash Flow

Operating Cash Flow

$53M

Free Cash Flow

-$23M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$970M

Total Liabilities

$374M

Stockholders' Equity

$596M

Cash & Equivalents

$272M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$489M	$489M	-0.1%
Gross Profit	$245M	$272M	-10.2%
Operating Income	$106M	$142M	-25.4%
Net Income	$52M	$63M	-17.6%